J&J's Imbruvica thumps GSK's Arzerra in head-to-head leukemia trial

Save

Results are in from a showdown between chronic lymphocytic leukemia drugs Imbruvica, from Johnson & Johnson's Janssen unit, and GlaxoSmithKline's Arzerra. And as it turns out, it wasn't much of a contest.